scholarly journals EPV285/#322 Human leukocyte antigen-g expression in vulvar squamous cell carcinoma

2021 ◽  
Author(s):  
N Boujelbene ◽  
I Zemni ◽  
W Babay ◽  
H Ben Yahia ◽  
S Dhouioui ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Leukocyte Antigen ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Human Leukocyte ◽  
Vulvar Squamous Cell Carcinoma ◽  
Leukocyte Antigen ◽  
Human Leukocyte Antigen G

Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis

2014 ◽  
Vol 161 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Jianyong Zheng ◽  
Chunsheng Xu ◽  
Dake Chu ◽  
Xiaoying Zhang ◽  
Jipeng Li ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Human Leukocyte Antigen ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Poor Prognosis ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Human Leukocyte Antigen G

Correlation between human leukocyte antigen-G expression and clinical parameters in oral squamous cell carcinoma

2018 ◽  
Vol 55 (4) ◽  
pp. 340 ◽  
Author(s):  
Gengsheng Shi ◽  
Xianjun Shen ◽  
Peng Wang ◽  
Panpan Dai ◽  
Bei Jin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Human Leukocyte Antigen ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Human Leukocyte ◽  
Clinical Parameters ◽  
Leukocyte Antigen ◽  
Human Leukocyte Antigen G

Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma

2011 ◽  
Vol 129 (6) ◽  
pp. 1382-1390 ◽  
Author(s):  
Aifen Lin ◽  
Xia Zhang ◽  
Wen-Jun Zhou ◽  
Yan-Yun Ruan ◽  
Dan-Ping Xu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Human Leukocyte Antigen ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Poor Prognosis ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Human Leukocyte Antigen G

scholarly journals Lesion human leukocyte antigen-E is associated with favourable prognosis for patients with oesophageal squamous cell carcinoma

2021 ◽  
Vol 49 (10) ◽  
pp. 030006052110472
Author(s):  
Yong-Fu Xu ◽  
Xue-Feng Du ◽  
Zhen-Yu Li ◽  
Zhe-Ping Fang ◽  
Fa-Biao Zhang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Leukocyte Antigen ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Primary Tumour ◽  
Human Leukocyte ◽  
Clinicopathological Characteristics ◽  
Oesophageal Squamous Cell Carcinoma ◽  
Leukocyte Antigen ◽  
Node Metastasis

Objective To investigate the clinical significance of human leukocyte antigen (HLA)-E levels in oesophageal squamous cell carcinoma (ESCC). Methods The levels of HLA-E immunostaining in ESCC lesions and 47 corresponding adjacent normal tissues were measured using immunohistochemistry. The correlation between the levels of immunostaining and clinical parameters was analysed. Results This study analysed 110 paraffin-embedded primary tumour lesions and 47 case–controlled paracancerous tissues that were surgically resected from 110 patients with ESCC. Positive immunostaining for HLA-E was observed in 88.2% (97 of 110) of ESCC lesions and 29.8% (14 of 47) of normal oesophageal tissues. There was no correlation between HLA-E immunostaining in ESCC lesions and clinicopathological characteristics such as lymph node metastasis, tumour–node–metastasis stage and differentiation grade. Kaplan–Meier survival analysis revealed a significantly better prognosis in patients with higher levels of HLA-E immunostaining than in those with lower levels of HLA-E immunostaining; overall survival was 28.6 months (95% confidence interval [CI], 23.2, 34.0) versus 15.3 months (95% CI, 11.5, 19.1), respectively. Furthermore, multivariate analysis showed that the HLA-E level was an independent prognostic factor in patients with ESCC. Conclusion A higher level of HLA-E immunostaining was associated with favourable survival in patients with ESCC.

scholarly journals Immunoexpression of human leukocyte antigen-DR in actinic cheilitis and lower lip squamous cell carcinoma

2019 ◽  
Vol 33 ◽  
Author(s):  
Luana Samara Balduíno de SENA ◽  
Hellen Bandeira de Pontes SANTOS ◽  
Marina Gonçalves do AMARAL ◽  
Manuel Antonio GORDÓN-NÚÑEZ ◽  
Pollianna Muniz ALVES ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Leukocyte Antigen ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Human Leukocyte ◽  
Actinic Cheilitis ◽  
Lower Lip ◽  
Leukocyte Antigen

scholarly journals Development of a Human Leukocyte Antigen Score to Predict Progression-Free Survival in Head and Neck Squamous Cell Carcinoma Patients

2018 ◽  
Vol 8 ◽  
Author(s):  
Gunnar Wichmann ◽  
Claudia Lehmann ◽  
Cindy Herchenhahn ◽  
Marlen Kolb ◽  
Mathias Hofer ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Leukocyte Antigen ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Human Leukocyte ◽  
Progression Free Survival ◽  
Neck Squamous Cell Carcinoma ◽  
Free Survival ◽  
Leukocyte Antigen

scholarly journals Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1118
Author(s):  
Zhiwei Wang ◽  
Ling Ran ◽  
Chunxia Chen ◽  
Ranran Shi ◽  
Yu Dong ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Human Leukocyte ◽  
Binding Model ◽  
Leukocyte Antigen ◽  
Specific Manner ◽  
Novel Strategy ◽  
Hla A2.1

Esophageal squamous cell carcinoma (ESCC), one of the deadliest gastrointestinal cancers, has had limited effective therapeutic strategies up to now. Accumulating evidence suggests that effective immunotherapy in cancer patients has been associated with T cells responsive to mutant peptides derived from neoantigens. Here, we selected 35 human leukocyte antigen-A2 (HLA-A2)-restricted mutant (MUT) peptides stemmed from neoantigens of ESCC. Among them, seven mutant peptides had potent binding affinity to HLA-A*0201 molecules and could form a stable peptide/HLA-A*0201 complex. Three mutant peptides (TP53-R267P, NFE2L2-D13N, and PCLO-E4090Q) of those were immunogenic and could induce the cytotoxic T lymphocytes (CTLs) recognizing mutant peptides presented on transfected cells in an HLA-A2-restricted and MUT peptide-specific manner. In addition, the CTL response in immunized HLA-A2.1/Kb transgenic (Tg) mice was enhanced by coupling MUT peptides to peptide WH, a peptide delivery carrier targeting Clec9a+ DCs. Then, the possible binding model conversions between the WT and MUT candidate peptides were analyzed by docking with the pockets of HLA-A*0201 molecule. We therefore propose a novel strategy and epitopes for immunotherapy of ESCC based on neoantigens.

Sign in / Sign up

Export Citation Format

Share Document